Please Wait.....
Report
Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031
Market Report I 2023-07-11 I 140 Pages I EMR Inc.
Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031
Global Neoantigen Cancer Vaccine Market Outlook:
The global neoantigen cancer vaccine market size was valued at USD 68.9 million in 2022, driven by the growing need for effective and personalized treatment across the globe. The market size is anticipated to grow at a CAGR of 69.4% during the forecast period of 2023-2031 to achieve a value of USD 8872.5 million by 2031.
Neoantigen Cancer Vaccine: Introduction
Neoantigen cancer vaccines are a novel approach to cancer immunotherapy that leverages the unique mutations found in individual tumors to stimulate the patient's immune system to specifically target and eliminate cancer cells. Neoantigens are tumor-specific antigens that arise from somatic mutations and are not present in normal tissues, making them ideal targets for personalized cancer vaccines.
The introduction of neoantigen cancer vaccines represents a significant advancement in precision medicine, as these vaccines can be tailored to each patient's specific tumor profile. By analyzing the genomic sequencing data of a patient's tumor, scientists can identify the neoantigens present and design a vaccine that specifically targets those antigens.
Key Trends in the Global Neoantigen Cancer Vaccine Market
Key Trends in neoantigen cancer vaccine development market include:
- Personalized Medicine: Neoantigen cancer vaccines exemplify the shift towards personalized medicine, as they are designed based on the unique genetic profile of each patient's tumor. This approach allows for targeted therapy and potentially improved treatment outcomes.
- Advances in Genomic Sequencing: The availability of next-generation sequencing technologies and bioinformatics tools has greatly facilitated the identification of neoantigens. The ability to rapidly and cost-effectively sequence tumor genomes has accelerated the development and application of neoantigen cancer vaccines.
- Combination Therapies: Neoantigen cancer vaccines are often used in combination with other treatment modalities, such as checkpoint inhibitors or chemotherapy. Combining these therapies can enhance the immune response and potentially improve patient outcomes.
- Vaccine Delivery Systems: Researchers are exploring various vaccine delivery systems, including nanoparticles, viral vectors, and RNA-based platforms, to enhance the effectiveness of neoantigen vaccines. These delivery systems aim to optimize the immune response and increase the durability of the vaccine's effects.
- Clinical Trials and Regulatory Pathways: Neoantigen cancer vaccines are currently being evaluated in clinical trials to assess their safety and efficacy. The results of these trials will help shape the regulatory pathways for their approval and subsequent commercialization.
- Collaboration and Partnerships: The development of neoantigen cancer vaccines often involves collaborations between academic institutions, pharmaceutical companies, and biotechnology firms. These partnerships leverage expertise and resources to advance research and accelerate the translation of these vaccines into clinical practice.
Global Neoantigen Cancer Vaccine Market Segmentations
Market Breakup by Product Type
- Personalized Neoantigen Vaccine
- Off-the Shelf Neoantigen Vaccine
Market Breakup by Neoantigen Type
- Synthetic Long Peptide (SLP)
- Dendritic Cell
- Nucleic Acid
- Tumor Cell
Market Breakup by Route of Administration
- Intravenous
- Intramuscular
- Transdermal
- Others
Market Breakup by Cell
- Autologous
- Allogenic
Market Breakup by Technology
- RNA Sequencing
- Whole Genome Sequencing
- HLA Typing
- Others
Market Breakup by Delivery Mechanism
- Liposomes
- Virosomes
- Electroporation
- Gene Gun
- Others
Market Breakup by Applications
- Lung, Melanoma
- Gastrointestinal
- Brain Cancer
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Neoantigen Cancer Vaccine Market Scenario
The market for neoantigen cancer vaccines is still in its early stages, but it holds immense potential for revolutionizing cancer treatment. Neoantigen cancer vaccines offer a personalized and targeted approach to fighting cancer by harnessing the power of the patient's immune system. As a result, they have garnered significant interest from researchers, pharmaceutical companies, and investors.
The market introduction of neoantigen cancer vaccines is driven by several factors. First and foremost, the rising incidence of cancer globally and the growing need for effective and personalized treatment options are propelling the demand for innovative therapies like neoantigen cancer vaccines.
Additionally, advancements in genomic sequencing technologies and bioinformatics tools have significantly accelerated the identification and characterization of neoantigens, making the development of neoantigen cancer vaccines more feasible and efficient.
Collaborations between academic institutions, pharmaceutical companies, and biotechnology firms are playing a crucial role in driving the market forward. These collaborations bring together the expertise and resources necessary to advance research, conduct clinical trials, and develop effective vaccines.
The market for neoantigen cancer vaccines is also influenced by regulatory pathways and reimbursement mechanisms. As clinical trials progress and promising results emerge, regulatory agencies are working to establish guidelines and approval processes specific to neoantigen vaccines. The successful navigation of these regulatory pathways will be crucial for market entry and commercialization.
Global Neoantigen Cancer Vaccine Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- OSE Immunotherapeutics SA
- Gritstone bio, Inc.
- BioNTech SE
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Merck & Co. Inc.
- Moderna Inc.
- Avidea Technologies, Inc.
- Eli Lilly and Company
- Vaccibody AS
- Agenus Inc.
- Novogene Co., Ltd.
- ZIOPHARM Oncology Inc.
- ISA Pharmaceuticals B.V.
- BrightPath Biotherapeutics Co., Ltd.
*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Neoantigen Cancer Vaccine Market Overview
3.1 Global Neoantigen Cancer Vaccine Market Historical Value (2016-2022)
3.2 Global Neoantigen Cancer Vaccine Market Forecast Value (2023-2031)
4 Global Neoantigen Cancer Vaccine Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter's Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Neoantigen Cancer Vaccine Market Segmentation
5.1 Global Neoantigen Cancer Vaccine Market by Product Type
5.1.1 Market Overview
5.1.2 Personalized Neoantigen Vaccine
5.1.3 Off-the Shelf Neoantigen Vaccine
5.2 Global Neoantigen Cancer Vaccine Market by Neoantigen Type
5.2.1 Market Overview
5.2.2 Synthetic Long Peptide (SLP)
5.2.3 Dendritic Cell
5.2.4 Nucleic Acid
5.2.5 Tumour Cell
5.3 Global Neoantigen Cancer Vaccine Market by Route of Administration
5.3.1 Market Overview
5.3.2 Intravenous
5.3.3 Intramuscular
5.3.4 Transdermal
5.3.5 Others
5.4 Global Neoantigen Cancer Vaccine Market by Cell
5.4.1 Market Overview
5.4.2 Autologous
5.4.3 Allogenic
5.5 Global Neoantigen Cancer Vaccine Market by Technology
5.5.1 Market Overview
5.5.2 RNA Sequencing
5.5.3 Whole Genome Sequencing
5.5.4 HLA Typing
5.5.5 Others
5.6 Global Neoantigen Cancer Vaccine Market by Delivery Mechanism
5.6.1 Market Overview
5.6.2 Liposomes
5.6.3 Virosomes
5.6.4 Electroporation
5.6.5 Gene Gun
5.6.6 Others
5.7 Global Neoantigen Cancer Vaccine Market by Applications
5.7.1 Market Overview
5.7.2 Lung, Melanoma
5.7.3 Gastrointestinal
5.7.4 Brain Cancer
5.7.5 Others
5.8 Global Neoantigen Cancer Vaccine Market by Region
5.8.1 Market Overview
5.8.2 North America
5.8.3 Europe
5.8.4 Asia Pacific
5.8.5 Latin America
5.8.6 Middle East and Africa
6 North America Neoantigen Cancer Vaccine Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Neoantigen Cancer Vaccine Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Neoantigen Cancer Vaccine Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.5 ASEAN
8.6 Australia
8.7 Others
9 Latin America Neoantigen Cancer Vaccine Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Neoantigen Cancer Vaccine Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Supplier Landscape
16.1 OSE Immunotherapeutics SA
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisition
16.1.5 Certifications
16.2 Gritstone bio, Inc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisition
16.2.5 Certifications
16.3 BioNTech SE
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisition
16.3.5 Certifications
16.4 F. Hoffmann-La Roche Ltd.
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisition
16.4.5 Certifications
16.5 Pfizer Inc.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisition
16.5.5 Certifications
16.6 Merck & Co. Inc.
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisition
16.6.5 Certifications
16.7 Moderna Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisition
16.7.5 Certifications
16.8 Avidea Technologies, Inc.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisition
16.8.5 Certifications
16.9 Eli Lilly and Company
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisition
16.9.5 Certifications
16.10 Vaccibody AS
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisition
16.10.5 Certifications
16.11 Agenus Inc.
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisition
16.11.5 Certifications
16.12 Novogene Co., Ltd.
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisition
16.12.5 Certifications
16.13 ZIOPHARM Oncology Inc.
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisition
16.13.5 Certifications
16.14 ISA Pharmaceuticals B.V.
16.14.1 Financial Analysis
16.14.2 Product Portfolio
16.14.3 Demographic Reach and Achievements
16.14.4 Mergers and Acquisition
16.14.5 Certifications
16.15 BrightPath Biotherapeutics Co., Ltd.
16.15.1 Financial Analysis
16.15.2 Product Portfolio
16.15.3 Demographic Reach and Achievements
16.15.4 Mergers and Acquisition
16.15.5 Certifications
17 Global Neoantigen Cancer Vaccine Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security